Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Early Delirium Detection With DeltaScan on Management of Underlying Delirium Causes in Critically Ill Patients. A Randomized Controlled Trial.

NCT05403268 is registered in ClinicalTrials.gov with Thomas Ottens as lead sponsor.

NCT NCT05403268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Early Delirium Detection With DeltaScan on Management of Underlying Delirium Causes in Critically Ill Patients. A Randomized Controlled Trial.
Lead sponsor
Thomas Ottens
Phase
Not applicable
Overall status
Completed
Start date
March 2, 2022
Completion date
August 19, 2025
Enrollment
131 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute encephalopathy, critical illness, delirium